Edwards Lifesciences did not expect to show much revenue growth in the first quarter 2021, but its total sales grew 5% year-over-year during the quarter, including 4% growth for its flagship Sapien transcatheter aortic valve replacement (TAVR) business.
“Our sales were dramatically impacted in the last few weeks of Q1 2020 as procedures fell due to COVID-19 disruptions